Prostate MRI for the detection of clinically significant prostate cancer: Update and future directions.

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-25 DOI:10.1016/bs.acr.2024.04.002
Shaun Trecarten, Abhijit G Sunnapwar, Geoffrey D Clarke, Michael A Liss
{"title":"Prostate MRI for the detection of clinically significant prostate cancer: Update and future directions.","authors":"Shaun Trecarten, Abhijit G Sunnapwar, Geoffrey D Clarke, Michael A Liss","doi":"10.1016/bs.acr.2024.04.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>In recent decades, there has been an increasing role for magnetic resonance imaging (MRI) in the detection of clinically significant prostate cancer (csPC). The purpose of this review is to provide an update and outline future directions for the role of MRI in the detection of csPC.</p><p><strong>Recent findings: </strong>In diagnosing clinically significant prostate cancer pre-biopsy, advances include our understanding of MRI-targeted biopsy, the role of biparametric MRI (non-contrast) and changing indications, for example the role of MRI in screening for prostate cancer. Furthermore, the role of MRI in identifying csPC is maturing, with emphasis on standardization of MRI reporting in active surveillance (PRECISE), clinical staging (EPE grading, MET-RADS-P) and recurrent disease (PI-RR, PI-FAB). Future directions of prostate MRI in detecting csPC include quality improvement, artificial intelligence and radiomics, positron emission tomography (PET)/MRI and MRI-directed therapy.</p><p><strong>Summary: </strong>The utility of MRI in detecting csPC has been demonstrated in many clinical scenarios, initially from simply diagnosing csPC pre-biopsy, now to screening, active surveillance, clinical staging, and detection of recurrent disease. Continued efforts should be undertaken not only to emphasize the reporting of prostate MRI quality, but to standardize reporting according to the appropriate clinical setting.</p>","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.acr.2024.04.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: In recent decades, there has been an increasing role for magnetic resonance imaging (MRI) in the detection of clinically significant prostate cancer (csPC). The purpose of this review is to provide an update and outline future directions for the role of MRI in the detection of csPC.

Recent findings: In diagnosing clinically significant prostate cancer pre-biopsy, advances include our understanding of MRI-targeted biopsy, the role of biparametric MRI (non-contrast) and changing indications, for example the role of MRI in screening for prostate cancer. Furthermore, the role of MRI in identifying csPC is maturing, with emphasis on standardization of MRI reporting in active surveillance (PRECISE), clinical staging (EPE grading, MET-RADS-P) and recurrent disease (PI-RR, PI-FAB). Future directions of prostate MRI in detecting csPC include quality improvement, artificial intelligence and radiomics, positron emission tomography (PET)/MRI and MRI-directed therapy.

Summary: The utility of MRI in detecting csPC has been demonstrated in many clinical scenarios, initially from simply diagnosing csPC pre-biopsy, now to screening, active surveillance, clinical staging, and detection of recurrent disease. Continued efforts should be undertaken not only to emphasize the reporting of prostate MRI quality, but to standardize reporting according to the appropriate clinical setting.

用于检测具有临床意义的前列腺癌的前列腺磁共振成像:最新进展和未来方向。
综述目的:近几十年来,磁共振成像(MRI)在检测具有临床意义的前列腺癌(csPC)方面发挥着越来越重要的作用。本综述旨在提供最新信息,并概述磁共振成像在检测前列腺癌中的作用的未来发展方向:在活检前诊断有临床意义的前列腺癌方面,进展包括我们对磁共振成像靶向活检的理解、双参数磁共振成像(非对比)的作用以及适应症的变化,例如磁共振成像在前列腺癌筛查中的作用。此外,磁共振成像在识别 csPC 方面的作用也日趋成熟,重点是在主动监测(PRECISE)、临床分期(EPE 分级、MET-RADS-P)和复发疾病(PI-RR、PI-FAB)方面实现磁共振成像报告的标准化。前列腺 MRI 在检测 csPC 方面的未来发展方向包括质量改进、人工智能和放射组学、正电子发射断层扫描 (PET)/MRI 和 MRI 引导治疗。应继续努力,不仅要重视前列腺 MRI 质量的报告,还要根据适当的临床环境对报告进行标准化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信